Main description:

This volume provides a state-of-the-art update on Fc Receptors (FcRs). It is divided into five parts. Part I, Old and New FcRs, deals with the long-sought-after FcR and the recently discovered FCRL family and TRIM21. Part II, FcR Signaling, presents a computational model of Fc RI signaling, novel calcium channels, and the lipid phosphatase SHIP1. Part III, FcR Biology, addresses major physiological functions of FcRs, their glycosylation, how they induce and regulate both adaptive immune responses and inflammation, especially in vivo, FcR humanized mice, and the multifaceted properties of FcRn. Part IV, FcRs and Disease, discusses FcR polymorphism, FcRs in rheumatoid arthritis and whether their FcRs make macaques good models for studying HIV infection. In Part V, FcRs and Therapeutic Antibodies, the roles of various FcRs, including Fc RIIB and Fc RI, in the immunotherapy of cancer and autoimmune diseases using monoclonal antibodies and IVIg are highlighted. All 18 chapters were written by respected experts in their fields, offering an invaluable reference source for scientists and clinicians interested in FcRs and how to better master antibodies for therapeutic purposes.

Contents:

Part I : Old and new FcRs

Hiromi Kubagawa, Yoshiki Kubagawa, Dewitt Jones, Tahseen H. Nasti, Mark Walter, and Kazuhito Honjo

The Old but New IgM Fc Receptor (Fc R)

F.J. Li, W.J. Won, E.J. Becker Jr., J.L. Easlick, E. Tabengwa, R. Li, M. Shakhmatov, P.D. Burrows, and R.S. Davis

Emerging Roles for FCRL Family Members in Lymphocyte Biology and Disease

Leo C. James

Intracellular antibody immunity and the cytosolic Fc receptor TRIM21

Part II: FcR signaling

Anna Niarakis, Yacine Bounab, Luca Grieco, Roman Roncagalli, Jerome Garin, Bernard Malissen, Marc Daeron, Denis Thieffry

Computational modeling of the main signaling pathways involved in mast cell activation

Tarik Attout, Andres Floto and Pierre Launay

Calcium channels in FcR signaling

Marcel Kuhny, Carolin N. Zorn, and Michael Huber

Regulation of Fc RI signaling by lipid phosphatases

Part III: FcR biology

Marc Daeron

Fc Receptors as Adaptive Immunoreceptors

Jerrard M Hayes, Eoin FJ Cosgrave, Weston B Struwe, Mark Wormald, Gavin P. Davey, Roy Jefferis, Pauline M Rudd

Glycosylation and Fc Receptors

Birgitta Heyman

Antibodies as natural adjuvants

Sanae Ben Mkaddem, Ivy Christou, Elisabetta Rossato, Laureline Berthelot, Agnes Lehuen and Renato C. Monteiro

IgA, IgA receptors and their anti-inflammatory properties

Stylianos Bournazos, David J. DiLillo and Jeffrey V. Ravetch

Humanized mice to study Fc R function

Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober and E. Sally Ward

FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.

Part IV: FcRs and disease

Xinrui Li, Andrew W Gibson and Robert P Kimberly

Human FcR polymorphism and disease.

Hanane el Bannoudi, Andreea Ioan-Facsinay and Rene E. M. Toes

Bridging auto-antibodies and arthritis; the role of Fc Receptors

P. Mark Hogarth, Jessica C. Anania, Bruce D. Wines

The Fc R of humans and non-human primates and their interaction with IgG: Implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies

Part V: FcRs and therapeutic antibodies

Ann L White, Stephen A Beers and Mark S. Cragg

FcgRIIB as a key determinant of agonistic antibody efficacy

Jantine E. Bakema and Marjolein van Egmond

Fc receptor dependent mechanisms of monoclonal antibody therapy of cancer; professionals at work

Sybille Boehm, Daniela Kao and Falk Nimmerjahn

Sweet and Sour: The role of glycosylation for the anti-inflammatory activity of immunoglobulin G